Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed cell death protein 1 (PD1)-Interleukin ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established ...

Contacts. IR United States Ran Meir (267) 468-4475 Israel Yael Ashman 972 (3) 914-8262 PR United States Kelley Dougherty (973) 658-0237 Israel Eden Klein 972 (3) 906-2645 Royalty Pharma Investor ...

Eric Hughes, Executive Vice President, Teva Global Research and Development (R&D) and Chief Medical Officer, said: “This partnership with Fosun Pharma in the development of our internally developed ...

FTC opens investigation into Teva, escalating patent fight with pharma industry. Democrats have accused drug companies of “junk patent listings,” arguing that the industry is blocking generic ...

Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed cell death protein 1 (PD1)-Interleukin ...

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 ...